Kuano uses OCI to create drug design platform to benefit Alzheimer’s research
The UK-based biotech research company enables better drug design by combining biomolecular simulation and AI on Oracle Cloud Infrastructure (OCI).
“Oracle has been vital to the success of our large-scale simulation and screening strategy, giving us the ability to rapidly deploy large sets of simulations to identify transition states, then efficiently screen against large libraries of candidate compounds or generate them using AI models.”
Kuano is a biotechnology research startup based in the UK that aims to redefine drug discovery with quantum computing and AI. The organization wanted to develop a drug design platform with new computational tools that would accelerate the creation of novel drugs while reducing the potential for toxic side effects and viral resistance in drug solutions. The company chose to run the platform on Oracle Cloud Infrastructure (OCI) because OCI offered a scalable cloud solution without the large upfront cost of on-premises computing. With OCI, the team was able to rapidly deploy large sets of simulations and efficiently transfer enormous libraries and models into an AI pipeline via OCI cloud storage. This massive increase in efficiency and speed allowed Kuano to explore new drug targets quickly and find new compounds much faster than in traditional timelines.